Halozyme Therapeutics (HALO) Common Equity (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Common Equity data on file, last reported at $219.6 million in Q1 2026.

• Common Equity for Q1 2026 came in at $219.6 million, down 54.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $219.6 million (down 54.46% YoY), and the FY2025 annual result was $48.8 million, down 86.58% from the prior year.
• Common Equity improved to $219.6 million in Q1 2026 per HALO's latest filing, from $48.8 million in the prior quarter.
• Over five years, Common Equity peaked at $503.9 million in Q3 2025 and troughed at $48.8 million in Q4 2025.
• A 5-year average of $249.5 million and a median of $249.2 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity jumped 334.11% in 2024, then tumbled 86.58% in 2025.
• A 5-year view of Common Equity shows it stood at $169.8 million in 2022, then slumped by 50.64% to $83.8 million in 2023, then jumped by 334.11% to $363.8 million in 2024, then plunged by 86.58% to $48.8 million in 2025, then surged by 349.94% to $219.6 million in 2026.
• Business Quant data shows HALO's Common Equity at $219.6 million in Q1 2026, $48.8 million in Q4 2025, and $503.9 million in Q3 2025.